Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 68
Selected: 0
NCT IDTitle
NCT03242252Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
NCT06933056Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
NCT02026063Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
NCT02300363DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin
NCT03315143Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
NCT01555008Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment
NCT01334242A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects
NCT00962065Study of LX4211 in Subjects With Type 2 Diabetes Mellitus
NCT02647918Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function
NCT01441232A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
NCT02383940Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C
NCT01188863Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus
NCT01417052A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis
NCT00853047Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
NCT03423446Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
NCT02147808A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects
NCT03292653Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
NCT02300350DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
NCT01104415Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
NCT01913002Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects
NCT00903383Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate
NCT01456052A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
NCT05696366Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
NCT01528111Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
NCT02155205A Thorough QT Study of Telotristat Etiprate
NCT00691808Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment
NCT01411800An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects
NCT02157558An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
NCT02926950Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
NCT01916850Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects
NCT06203002A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
NCT01932528An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
NCT03302845A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
NCT07211802CKM For Safe Use of SGLT2i in Type 1 Diabetes
NCT06217302Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
NCT02157584An Open-Label Food Effect Study of Telotristat Etiprate
NCT04455633Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
NCT02531035A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
NCT01292993A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects
NCT02195635Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
NCT03242018A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
NCT02494609Oral Contraceptive DDI Study
NCT02459899Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
NCT04034745Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
NCT00847886Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis
NCT03386344Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
NCT03351478Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
NCT02471274PK Study of Sotagliflozin in Subjects With Hepatic Impairment
NCT02421510Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
NCT01494233A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome